ISN Nexus 2016 Symposia
Standard
ISN Nexus 2016 Symposia : Translational Immunology in Kidney Disease—The Berlin Roadmap. / Anders, Hans Joachim; Rovin, Brad; Jayne, David; Brunetta, Paul; Coppo, Rosanna; Davidson, Anne; Devarapu, Satish Kumar; de Zeeuw, Dick; Duffield, Jeremy; Eulberg, Dirk; Fierro, Alberto; Floege, Jürgen; Frese, Steffen; Guillevin, Loïc; Holdsworth, Stephen; Hughes, Jeremy; Kettritz, Ralph; Kluger, Malte; Krebs, Christian; Lapteva, Larissa; Levin, Adeera; Li, Jinhua; Lightstone, Liz; Mack, Matthias; Mansouri, Ladan; McAdoo, Stephen; McKinney, Eoin; Panzer, Ulf; Parikh, Samir; Pusey, Charles; Putterman, Chaim; Rabelink, Ton; Radbruch, Andreas; Rees, Andrew; Reilly, Mary; Reinders, Marlies; Remuzzi, Giuseppe; Ruggenenti, Piero; Sacks, Steven; Schall, Thomas J.; Meyer-Schwesinger, Catherine; Sharma, Kumar; Suzuki, Yusuke; Tomas, Nicola M.; Zhao, Ming Hui.
in: KIDNEY INT REP, Jahrgang 1, Nr. 4, 2016, S. 327-339.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - ISN Nexus 2016 Symposia
T2 - Translational Immunology in Kidney Disease—The Berlin Roadmap
AU - Anders, Hans Joachim
AU - Rovin, Brad
AU - Jayne, David
AU - Brunetta, Paul
AU - Coppo, Rosanna
AU - Davidson, Anne
AU - Devarapu, Satish Kumar
AU - de Zeeuw, Dick
AU - Duffield, Jeremy
AU - Eulberg, Dirk
AU - Fierro, Alberto
AU - Floege, Jürgen
AU - Frese, Steffen
AU - Guillevin, Loïc
AU - Holdsworth, Stephen
AU - Hughes, Jeremy
AU - Kettritz, Ralph
AU - Kluger, Malte
AU - Krebs, Christian
AU - Lapteva, Larissa
AU - Levin, Adeera
AU - Li, Jinhua
AU - Lightstone, Liz
AU - Mack, Matthias
AU - Mansouri, Ladan
AU - McAdoo, Stephen
AU - McKinney, Eoin
AU - Panzer, Ulf
AU - Parikh, Samir
AU - Pusey, Charles
AU - Putterman, Chaim
AU - Rabelink, Ton
AU - Radbruch, Andreas
AU - Rees, Andrew
AU - Reilly, Mary
AU - Reinders, Marlies
AU - Remuzzi, Giuseppe
AU - Ruggenenti, Piero
AU - Sacks, Steven
AU - Schall, Thomas J.
AU - Meyer-Schwesinger, Catherine
AU - Sharma, Kumar
AU - Suzuki, Yusuke
AU - Tomas, Nicola M.
AU - Zhao, Ming Hui
N1 - Funding Information: We thank the International Society of Nephrology for hosting the Nexus meeting and the industry sponsors for their unrestricted educational support. The study was supported by the European Union's Horizon 2020 research and innovation program under grant agreement No. 668036 (RELENT). This report was further supported by the EU 7FP project REDDSTAR (No. 305736) and the HORIZON2020 project NEPHSTROM (No. 634086). The views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out. Alberto Fierro, Chile, was supported by “Fondecyt regular 1120731.” Publisher Copyright: © 2016 International Society of Nephrology Copyright: Copyright 2016 Elsevier B.V., All rights reserved.
PY - 2016
Y1 - 2016
N2 - To date, the treatment of immune-mediated kidney diseases has only marginally benefited from highly specific biological drugs that have demonstrated remarkable effects in many other diseases. What accounts for this disparity? In April 2016, the International Society of Nephrology held a Nexus meeting on Translational Immunology in Nephrology in Berlin, Germany, to identify and discuss hurdles that block the translational flow of target identification, and preclinical and clinical target validation in the domain of immune-mediated kidney disease. A broad panel of experts including basic scientists, translational researchers, clinical trialists, pharmaceutical industry drug developers, and representatives of the American and European regulatory authorities made recommendations on how to overcome such hurdles at all levels of the translational research process. The results of these discussions are presented here, which may serve as a roadmap for how to optimize the process of developing more innovative and effective drugs for patients with immune-mediated kidney diseases.
AB - To date, the treatment of immune-mediated kidney diseases has only marginally benefited from highly specific biological drugs that have demonstrated remarkable effects in many other diseases. What accounts for this disparity? In April 2016, the International Society of Nephrology held a Nexus meeting on Translational Immunology in Nephrology in Berlin, Germany, to identify and discuss hurdles that block the translational flow of target identification, and preclinical and clinical target validation in the domain of immune-mediated kidney disease. A broad panel of experts including basic scientists, translational researchers, clinical trialists, pharmaceutical industry drug developers, and representatives of the American and European regulatory authorities made recommendations on how to overcome such hurdles at all levels of the translational research process. The results of these discussions are presented here, which may serve as a roadmap for how to optimize the process of developing more innovative and effective drugs for patients with immune-mediated kidney diseases.
KW - autoimmunity
KW - inflammation
KW - lupus
KW - rejection
KW - stem cells
KW - vasculitis
UR - http://www.scopus.com/inward/record.url?scp=84995563999&partnerID=8YFLogxK
U2 - 10.1016/j.ekir.2016.06.009
DO - 10.1016/j.ekir.2016.06.009
M3 - SCORING: Journal article
AN - SCOPUS:84995563999
VL - 1
SP - 327
EP - 339
JO - KIDNEY INT REP
JF - KIDNEY INT REP
SN - 2468-0249
IS - 4
ER -